Final Program

SUNDAY • MAY 15 31
• learn about the mechanistic underpinnings of the interactions between
sleep-disordered breathing and heart failure and consequent effects of patient
outcomes;
• apply appropriate patient selection practices to identify candidates for novel
emerging therapies for obstructive sleep apnea other than CPAP therapy;
• understand the relationship between sleep-disordered breathing and cancer and
whether this can be translated into practice.
Sleep medicine is at the cusp of major advancements and impact on population
health and well-being. However, there are thorny issues that have emerged as areas
of controversies that need to be debated. While cardiovascular disease and cancer
remain top killers, the role of treatment of sleep disordered breathing in patients with
heart failure, and the relationship between sleep-disordered breathing and cancer
are hotly debated. Moreover, emerging treatments for sleep-disordered breathing
are rapidly changing the landscape as they disrupt and find their rightful place in the
treatment hierarchy. This symposium features “world” heavy-weights in the
respective areas of sleep medicine who will “reconcile” their differences while
keeping bloodshed to a minimum. Attendees will learn about the mechanistic
underpinnings of the interactions between sleep, heart failure and cancer; the clinical
implications of such complex interactions; and emerging treatment approaches to
sleep disordered breathing. This symposium is not for the weak hearted.
Chairing: N.A. Antic, MBBS, PhD, Adelaide, Australia
S. Parthasarathy, MD, Tucson, AZ
J.P. Bakker, PhD, Boston
9:00 PRO: Should We Treat Sleep Disordered Breathing in Heart
Failure?
D. Bradley, MD, Toronto, Canada
9:20 CON: Should We Treat Sleep Disordered Breathing in Heart
Failure?
M. Naughton, MBBS, MD, East Melbourne, Australia
9:40 PRO: Sleep Disordered Breathing Causes Cancer?
R. Farre, PhD, Barcelona, Spain
10:00 CON: Sleep Disordered Breathing Causes Cancer?
C.P. O’Donnell, PhD, Pittsburgh, PA
10:20 PRO: There Will Never Be a Superior Treatment for OSA than
CPAP
C. Sullivan, MBBS, PhD, Sydney, Australia
10:40 CON: There Will Never Be a Superior Treatment for OSA than
CPAP
D.P. White, MD, Denver, CO
There will be a 5-minute discussion after each talk.
Target Audience
Neonatologists, pediatric pulmonologists, basic scientists interested in lung
development, inflammation, genetic basis of disease and stem cell biology.
Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings about molecular targets important in the pathogenesis of
BPD identified through animal and human studies;
• apply stem cell based approaches to their patients in order to improve
outcomes in BPD;
• describe new advances in the molecular understanding of the timing of
normal birth and the importance of fetal lung maturity and inflammation in
the process of initiation of labor.
Bronchopulmonary dysplasia (BPD) continues to be a major cause of morbidity
and mortality for prematurely born infants. This session will highlight recent
advances in our understanding of the causes of BPD from newer mouse models
and large-scale human genetic studies, contributions of the lung microbiome to
neonatal disease, and newer approaches to therapy using cell based therapies,
as well as new links to understanding the causes of timing of parturition, as
prevention of preterm birth is the ultimate therapy for the prevention of BPD.
Chairing: L.M. Nogee, MD, Baltimore, MD
B. Thebaud, MD, PhD, Ottawa, Canada
9:00 Chronic Lung Injury Induced by Ventilation: Insights from
Neonatal Mouse Models
R. Bland, MD, Stanford, CA
9:20 The Lung Microbiome and Chronic Lung Disease in the
Premature Infant
A. Hamvas, MD, Chicago, IL
9:40 Genomic Approach to Understanding BPD
N. Ambalavanan, MD, Birmingham, AL
9:55 Honing in on Rare Variants Contributing to BPD
H.M. O’Brodovich, MD, Stanford, CA
10:10 Cell Based Therapies for BPD
B. Thebaud, MD, PhD, Ottawa, Canada
10:30 Lung Maturation, Inflammation and the Timing of Parturition
C. Mendelson, PhD, Dallas, TX
10:50 Discussion
B. Thebaud, MD, PhD, Ottawa, Canada
L.M. Nogee, MD, Baltimore, MD
There will be a 5-minute discussion after each talk.
SUNDAY MORNING
A10
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
NEW INSIGHTS INTO THE PATHOGENESIS AND
TREATMENT OF BRONCHOPULMONARY
DYSPLASIA
Assemblies on Pediatrics; Respiratory Cell and Molecular Biology
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 3007/3009 (West Building, Level 3)
A11
BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
GLOBAL LUNG CANCER HEALTH ISSUES
Assemblies on Behavioral Science and Health Services Research;
Clinical Problems; Environmental, Occupational and Population Health;
Thoracic Oncology
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 303/305 (South Building, Esplanade Level)
ATS 2016 • San Francisco